Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 954 participants.
Also called NCT03332771
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 954 participants
- Sponsor
- Registry
-
NCT03332771 -
2016-001801-17
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Hungary, Slovakia
- Registry status
- Completed
Technical summary
Registry record NCT03332771. Randomized; quadruple masking; primary purpose treatment. Start 2017-12-01 (actual); primary completion 2019-08-06 (actual). Results posted on 2021-05-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
- Acronym
- SOTA-GLIM
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sotagliflozin (SAR439954)
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Lead sponsor
- Lexicon Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct03332771- Content hash
2563c9fb63eac4ba586521af143566f8fca057dee07b58914769f35c55636ceb